MxT Biotech develops the Hydroporator®, a non-viral microfluidic platform for efficient delivery of cargos like DNA, mRNA, and proteins into primary cells. This technology offers high delivery efficiency, viability, and scalability, avoiding limitations associated with viral transduction or electroporation. The platform supports advancements in cellular engineering, genome editing, and cancer immunotherapy research and manufacturing.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for delivering genetic material into cells, such as viral transduction and electroporation, often suffer from limitations including low efficiency, toxicity, high costs, and challenges in maintaining cell viability and functionality, especially when working with primary cells. These limitations hinder advancements in fields like cancer immunotherapy, cellular engineering, and genome editing.
Solution
Mxt Biotech's Hydroporator® is a non-viral microfluidic platform designed for efficient intracellular delivery of plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles into primary cells. The Hydroporator® technology enables high delivery efficiency, maintains cell functionality and viability, and offers high scalability. The system provides a new avenue to accelerate cancer immunotherapy, cellular engineering, and genome editing, overcoming the challenges associated with viral transduction, lipofection, and electroporation.
Target Audience
The primary users are researchers and companies in cancer immunotherapy, cellular engineering, and genome editing, particularly those working with primary cells and requiring efficient and scalable delivery methods.
Features
- Fully automated intracellular delivery with high efficiency.
- Maintains high cell viability and functionality post-transfection.
- Scalable capacity up to 10 million cells per run.
- Suitable for plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles.
- Addresses limitations of viral transduction, lipofection, and electroporation.
- Available in a Research Use Only (RUO) format.
- GMP-compliant Hydroporator is under development for CGT manufacturing.